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Abstract
c-Rel is a member of the Rel/NF-kB transcription factor family and is predominantly expressed in lymphoid and myeloid
cells, playing a critical role in lymphocyte proliferation and survival. Persistent activation of the c-Rel signal transduction
pathway is associated with allergies, inflammation, autoimmune diseases, and a variety of human malignancies. To explore
the potential of targeting c-Rel as a therapeutic agent for these disorders, we designed a small interfering RNA (siRNA) to
silence c-Rel expression in vitro and in vivo. C-Rel-siRNA expression via a retroviral vector in a B cell tumor cell line leads to
growth arrest and apoptosis of the tumor cells. Silencing c-Rel in primary B cells in vitro compromises their proliferative and
survival response to CD40 activation signals, similar to the impaired response of c-Rel knockout B cells. Most important, in
vivo silencing of c-Rel results in significant impairment in T cell-mediated immune responses to antigenic stimulation. Our
study thus validates the efficacy of c-Rel-siRNA, and suggests the development of siRNA-based therapy, as well as small
molecular inhibitors for the treatment of B cell tumors as well as autoimmune diseases.
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Introduction
RNA interference (RNAi)-mediated gene silencing has been a
powerful approach for functional studies of a particular gene in
biological systems [1,2]. At present, several clinical trials are
ongoing to test small interfering RNA (siRNA)-based therapies for
age-related macular degeneration and viral diseases [1,2]. The
Rel/NF-kB transcription factors have been considered important
therapeutic targets, because their persistent activation can lead to
tumorigenesis, inflammation, and autoimmunity [3–8]. The
purpose of this report is to provide a proof-of-concept study to
demonstrate the feasibility of targeting the c-Rel member of the
Rel/NF-kB family as potential therapy for B cell tumor and
inflammatory disorders.
The mammalian Rel/NF-kB transcription factor family con-
tains five members: c-Rel, p50, p65, RelB, and p52. Due to their
differential tissue expression pattern and target gene specificities,
the five Rel/NF-kB members play distinctly unique roles in
biology and disease [8–12]. Earlier studies have shown that p50
and p65 are ubiquitously expressed in all tissue types, whereas the
other three members (c-Rel, p52, and RelB) are predominantly
expressed in differentiated lymphoid and myeloid cells [13–16].
Subsequent studies using gene targeting approaches further
demonstrated the distinctive phenotype and disease susceptibility
of individual Rel/NF-kB knockout mice. For example, due to
restricted expression of c-Rel, RelB, and p52 in hematopoietic
cells, these knockout mice are viable and only exhibit impairment
in the immune cells [17–25]. By contrast, p65 knockout mouse
exhibit early embryonic lethality resulting from extensive hepato-
cyte apoptosis [26,27].
Substantial evidence has further suggested that c-Rel is
particularly noteworthy as a desirable therapeutic target, among
the Rel/NF-kB family. The c-Rel proto-oncogene is the cellular
counterpart of the v-Rel oncogene originally discovered in an
avian retrovirus that causes acute lymphoma in chickens [7,28]. C-
Rel gene amplification or persistent activation has been detected in
many human B cell tumors, including diffuse large B cell
lymphomas, primary mediastinal lymphoma, CLL, and multiple
myeloma, as well as in some solid tumors [29–45]. Perhaps the
most intriguing findings come from a series of studies assessing the
tumorigenic potential of the Rel members. The systematic analyses
unequivocally demonstrate that c-Rel is the most oncogenic
member among the Rel/NF-kB family [28,29,31,32,46,47], thus
supporting its critical role in tumorigenesis.
The role of c-Rel in biology and disease has also been addressed
by the use of c-Rel knockout mice. Since c-Rel expression is
restricted to mature hematopoietic cells, c-Rel knockout exhibit
deficiencies only in the immune response to antigens [8,48–51].
Otherwise, the c-RelKO mice are viable and have a normal life
span. Due to c-Rel defects in lymphocytes and myeloid cells, the c-
RelKO mice do not develop allergic inflammation, autoimmune
diseases (EAE, Type I diabetes, collagen induced arthritis), or
reject allogeneic transplants [17–22]. Nonetheless, their innate
immune responses to pathogens (e.g. influenza virus, Toxoplasma
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suggesting that blocking c-Rel pharmacologically may not cause
severe global immunosuppression.
c-Rel is involved in autoimmune diseases and cancer via
regulation of the expression of cytokines, anti-apoptotic mole-
cules, and cell cycle regulators. At least 11 cytokine genes have
been shown to be c-Rel targets, including TNF-a, IL-1, IL-2, IL-
6, IL-10, IL-12, IL-15, IL-17, IL-23, IL-27, and IFN-c.I n
addition, c-Rel controls the expression of cell cycle molecules
(E2F3a, cyclin D2/3, cyclin E), survival proteins (BclX, Bfl1,
Mcl-1), signaling molecules, growth factors, and transcription
factors [18,19,48,50,55–68]. Therefore, the c-RelKO mouse as
well as oncogenic transformation studies support the rationale for
considering c-Rel as an attractive therapeutic target for
autoimmune/inflammatory diseases and B cell tumors, in that
blocking c-Rel (i) may inhibit the production of inflammatory
cytokines and tumorigenic factors, but (ii) does not cause systemic
tissue toxicity, as c-Rel function is confined to the hematopoietic
cells, and (iii) would not cause global immunosuppression, since
innate immunity against pathogens remains largely intact in
c-RelKO mice.
To explore the therapeutic potential of targeting c-Rel, we
designed a small interfering RNA (siRNA) to silence c-Rel in B cell
lymphoma as well as in immune cells. Our data reveal that, upon
silencing c-Rel in a B cell tumor line, the cells undergo growth
arrest and apoptosis in a dose-dependent manner. Intriguingly, in
vivo silencing c-Rel renders the mice less responsive to antigenic
stimulation, mimicking the impaired immune phenotype of the
c-Rel knockout mice.
Results
Generation of c-Rel silencing retroviral construct
One of the hurdles in developing siRNA-based therapy is
delivery of siRNA into cells and tissues. Since our initial purpose
was to validate c-Rel as a potential therapeutic target, we utilized a
retrovirus to deliver siRNA, as these agents have a higher
transduction efficiency in tumor cell lines and primary cells, which
are often resistant to conventional DNA transfection methods.
To generate a c-Rel-siRNA, we selected a 21-nucleotide (nt)
sequence unique to murine c-Rel coding sequences that would
enable efficient knockdown of its mRNA using the rules solicited
by previous empirical studies [69–72]. The c-Rel-silencing
oligonucleotides were first cloned into the pEGFP-mU6-1 vector,
immediately downstream of its U6 promoter (Fig. 1a) [73,74].
The siRNA-expressing cassette was then sub-cloned into the Bgl II
and Hpa I sites of the MIGR1 vector to generate a new construct,
MIGR1-mU6-siRel. The presence of an IRES sequence followed
by the green fluorescent protein (GFP) gene in the MIGR1 vector
allows a co-expression of c-Rel siRNA duplex and the GFP, the
latter being used for monitoring transduction efficiency. This
vector was co-transfected with two packaging plasmids into 293T
cells, following the procedure described in our previous studies
[73–75]. Virus was harvested from the cell culture supernatant
and contained a titer of ,5610
6/ml.
Silencing of c-Rel
To test the silencing effect of the c-Rel-siRNA retrovirus, we
utilized NIH3T3 cells that express c-Rel constitutively. The cells
Figure 1. In vitro silencing of c-Rel. (a) Diagram of retroviral vector and c-Rel-siRNA. (b) 2610
5 of NIH3T3 cells in 4 ml of DMEM were seeded in 6-
cm dishes and were cultured for 24 hours before addition of 100 ml of c-Rel siRNA expressing retrovirus or control virus (virus titer: 5610
6/ml). At
48 hours post-infection, cells were harvested and monitored by flow cytometry for the infection efficiency. (c) Cell lysates were prepared from the
virus-infected NIH3T3 cells. 30 mg of the cell lysates were loaded onto 12% SDS-PAGE gel that was transferred onto nylon membrane. The membrane
was Western blotted with c-Rel specific polyclonal antibody. After stripping off the c-Rel specific antibody, membrane was re-blotted with CDK2
specific antibody. When normalized to CDK2 level, the c-Rel expression in the MIGR1U6 and MIGR1U6-siRel group is 1.22 and 0.43, respectively,
indicating ,65% reduction of c-Rel expression in this particular c-Rel silenced sample.
doi:10.1371/journal.pone.0005028.g001
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infection, cells were harvested and analyzed for percentage of
GFP+ cells by flow cytometry to quantify infection efficiency
(Fig. 1b). The infection efficiencies for c-Rel-siRNA and control
viruses were 71% and 91% respectively. Cell lysates were then
prepared and subjected to Western blot analysis for c-Rel protein
expression. By densitometry, a 70% reduction of c-Rel protein was
observed in the cells transduced with c-Rel-siRNA as compared to
the control cells (Fig. 1c), indicating that the siRNA is effective in
reducing c-Rel expression.
Silencing c-Rel resulted in diminished cell survival and
cell cycle progression of a B cell tumor line
c-Rel overexpression or gene amplification has been reported in
a variety of B cell tumors [29–32]. To validate c-Rel as a potential
drug target for B cell tumors, we applied c-Rel-siRNA to B cell
tumors expressing constitutive c-Rel activity. The murine B cell
tumor line, Wehi-231, expresses high levels of c-Rel and p50 that
are required for maintaining its survival and proliferation [13,76–
86]. To facilitate retroviral infection efficiency and integration into
cycling cells, we utilized anti-CD40 to stimulate the proliferation of
Wehi-231. Another reason we chose anti-CD40 is that CD40
signaling pathway leads to the activation of c-Rel, thus allowing us
to investigate the role of c-Rel in B cell proliferation. We observed
a viral dose-dependent increase in infection efficiency for both
samples transduced with either cRel-siRNA or control viruses, as
measured by GFP+ cell percentage (Figure 2a). Although the
infection efficiency was comparable for both viral stocks, there was
a noticeably lower percentage of GFP+ population in the c-Rel-
siRNA infected Wehi-231 sample compared to the controls (e.g.
15% vs 49% at 2.5610
6/ml sample) forty eight hours post-
infection. Since c-Rel is required for the expression of Bcl-X,
c-myc, and other survival molecules in Wehi-231 cells
[76,77,79,80,87,88], the lower percentage of GFP+ cells in the
c-Rel-siRNA samples may be indicative of cell apoptosis induced
by the expression of the specific siRNA. To further investigate this
issue, we analyzed the cells by propidium iodide (PI) staining to
quantify cell survival and proliferation. We observed a dose-
dependent reduction in cell survival in the c-Rel silencing groups
(Fig. 2b, 2c). Concomitant with increased apoptosis, the c-Rel
silencing groups also have significantly reduced cell cycle
progression, as enumerated by the percentage of cells in the S/
G2/M phase. An attempt to perform PI and GFP double staining
was unsuccessful due to an interference of GFP signal by PI.
Figure 2. Silencing c-Rel resulted in diminished cell survival and cell cycle progression in Wehi-231 cells. (a) 2 ml of Wehi-231 cells
(2610
6/ml) were cultured in a 6-well plate with anti-CD40 (10 mg/ml) for 48 hours in the presence of polybrene (4 mg/ml) and different dosages of
the c-Rel siRNA expressing retrovirus or the control virus (0.3125, 0.625, 1.25, and 2.5610
6). Cells were harvested and monitored by flow cytometry for
the percentage of GFP
+ cells. c-Rel silencing was confirmed by western blot analysis. (b) Cell survival and cell cycle progression was analyzed by PI
staining. The number of percentage in M1 indicates the percentage of the analyzed cells undergoing apoptosis. The number in M2 representing the
number of cells entering into cell cycle. (c) Data in (b) were summarized as line chart type figure.
doi:10.1371/journal.pone.0005028.g002
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cell growth and survival of Wehi-231 tumor cell line and validated
the use of c-Rel-siRNA in inducing growth arrest and apoptosis of
B cell tumors with constitutive c-Rel activity.
Silencing c-Rel in primary B cells leads to decreased cell
survival and proliferative response to mitogenic
stimulation
We and others have previously utilized the c-Rel knockout mice
to show that blocking c-Rel in B and T lymphocytes resulted in
impaired cell proliferation and survival response to mitogenic and
antigenic stimulation [48,50,51,55,56,59–62,64,85,89–92]. To
further validate the use of c-Rel-siRNA in primary cells, we
stimulated primary B cells with anti-CD40 to trigger cell
proliferation 24 hours prior to infection with either the control
or c-Rel siRNA expressing retrovirus. We anticipated that
silencing c-Rel in primary B cells should render the cells less
responsive to mitogenic stimulation, just like c-Rel knockout
lymphocytes. In both control and the c-Rel-siRNA groups, only
about 11% of the cells could be infected (Figure 3a). The
percentage is consistent with the portion of cells entering the cell
cycle during a 48-hour activation period. Nonetheless, we
observed that B cells infected with c-Rel siRNA virus had an
increased percentage of apoptotic cells (31.5%) and decreased
percentage of cells in cell cycle progression (5.8%), compared to
the control group (20%, 8.8%), as measured by PI staining
(Fig. 3b). Since PI emission wavelength overlaps with that of GFP,
it was impossible to distinguish the proliferative/survival events
within GFP+ cell population. Therefore, we utilized anti-Ki-67 to
detect the nuclear antigen Ki-67, which is present during all active
phases of the cell cycle (G1, S, G2, and mitosis), but is absent from
resting cells (G0). A secondary antibody conjugated with
allophycocyanin (excitation 650, emission 660) was then used to
detect Ki-67-expressing cells. By gating on the GFP+ population
indicative of retroviral infected cells, we observed a decreased
staining of Ki-67 in the c-Rel silencing group as compared to the
control group (6.9% vs 11%) (Fig. 3c). These results are consistent
with the reduced cell growth and survival response to CD40,
antigenic, and mitogenic signals in B cells derived from the c-Rel
knockout mice [48,50,51,55,56,59–62,64,85,89–92].
c-Rel knockdown lymphocytes have impaired
proliferative and survival responses to mitogenic signals
To further validate the use of c-Rel-siRNA in the context of the
entire animal, we generated c-Rel knockdown chimeric mice by
reconstituting the bone marrow of irradiated recipient mice with
the bone marrow cells infected with c-Rel-siRNA or control
viruses, as previously described [73–75] (also see Materials and
Methods). Two months post-reconstitution, some chimeric mice
from a group of 8–10 mice per experiment were used for in vitro
Figure 3. In vitro silencing of c-Rel led to impaired cell survival and cell cycle progression in primary B cells. (a) Primary B cells isolated
from mouse spleen were stimulated for 24 hr with anti-CD40 (10 mg/ml) before addition of the retroviruses. Cells were harvested at 48 hr post-
infection and were monitored by flow cytometry for the infection efficiency. (b) Cell survival and cell cycle progression was analyzed by PI staining.
(c) Cells harvested from the same culture in (a) were stained with anti-Ki-67 using intracellular staining methods and analyzed by flow cytometry. The
number represents the percentage of Ki-67 positive cells within the GFP
+ population.
doi:10.1371/journal.pone.0005028.g003
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experiments. Reconstitution of lymphoid cells in the chimeric mice
by donor bone borrow cells were enumerated. Total cell number
in spleen is 110–130610
6, with an average of 30–50% GFP+ cells
in both T and B cell lineages (data not shown). Additionally, there
is no significant difference in the total lymphoid cell number or
GFP+ percentage between c-Rel-siRNA and MIGR1 transduced
mice. This is consistent with previous findings that c-Rel knockout
mice have normal development of B and T cell lineage [48,50].
Splenic B cells from the chimeric mice were stimulated for 48 hr
with different mitogens: anti-IgM, anti-CD40, and LPS. Cell
proliferation was monitored by thymidine incorporation. As
shown in Figure 4a, the c-Rel silencing group had a reduced
cell proliferation in response to all three mitogens tested. The
percentage of inhibition was 35.3% (anti-IgM), 41.3% (anti-
CD40), and 29.6% (LPS), respectively. The reduced response to
CD40 signaling was further confirmed by PI staining analysis,
which showed that over 10% more cells underwent apoptosis and
fewer cells entered into cell cycles in the c-Rel silencing group.
When only the GFP+ population was analyzed by Ki-67 staining
assay, there were significantly less proliferative cells in the c-Rel-
siRNA group than the control group (15.5% vs 25%) (Fig. 4b).
c-Rel-siRNA chimeric mice exhibited impaired immune
responses to antigen
c-RelKO mice have impaired immune responses to a variety of
antigens, including foreign protein antigens, auto-antigens, and
allo-antigens [18,19,21,22,48–50,93–95]. To validate that c-Rel-
siRNA mimics the biological effect of the c-RelKO, we tested the
bone marrow chimeric mice for proliferative responses to KLH as
a foreign protein antigen. The chimeric mice transduced with
either c-Rel-siRNA or control viruses were immunized with KLH
(100 mg) through the hind footpad. Nine days later, lymphocytes
were isolated from spleen and lymph node and cultured with KLH
at increasing concentrations. Lymphocyte proliferation was
monitored by thymidine incorporation 48 hours later. Our data
Figure 4. In vivo silencing c-Rel led to impaired cell survival and cell cycle progression in primary B cells. (a) Primary B cells isolated
from the chimeric mouse spleen (either silencing mice or control mice) (See Materials and Methods) were stimulated for 48 hr respectively with anti-
IgM (10.0 mg/ml), anti-CD40 (10.0 mg/ml), and LPS (10.0 mg/ml). Cells were pulsed with 0.5 mci of
3H-thymidine for 6 hours before harvest and
assayed for
3H-thymidine incorporation. Total cell number in spleens of reconstituted mice is 110–130610
6, with an average of 30–50% GFP+ cells in
both T and B cell lineages. The total lymphoid cell number or GFP+ percentage between c-Rel-siRNA and MIGR1 transduced mice are comparable. (b)
B cells stimulated with anti-CD40 in (a) were further analyzed respectively by PI staining for cell survival and cell cycle progression, and by Ki-67
staining for cell proliferation.
doi:10.1371/journal.pone.0005028.g004
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from the c-Rel silencing group exhibited a significantly impaired T
cell proliferative response to antigen re-stimulation as compared to
that of the control group (Fig. 5). C-Rel silencing in splenocytes
and lymph node cells led to a respective 27.3% and 40% inhibition
in proliferative responses to 100 ug/ml KLH stimulation.
Collectively, our data suggest that in vivo silencing of the c-Rel
molecule can be achieved by delivering c-Rel-specific siRNA with
retroviral mediated transduction and that partial c-Rel-knockdown
in vivo results in a detectable reduction in lymphocyte proliferative
responses to a protein antigen.
Discussion
In this report, we demonstrate that retrovirus-mediated delivery
of c-Rel specific siRNA results in significantly reduced cell survival
and cell cycle progression for both B cell lymphoma and primary B
cells. In vivo c-Rel knockdown further impairs an immune
responses to antigenic stimulation, similar to the phenotypic
response of the c-Rel knockout mice. Our data thus validate c-Rel
as a target, and the use of c-Rel-siRNA as a potential intervention
tool for the treatment of B cell tumors, inflammation, and
autoimmune diseases.
Previous studies have shown that the Wehi-231 B cell tumor line
expresses constitutively active NF-kB activity primarily composed
of c-Rel and p50 [13,76–86]. These cells are dependent on NF-kB
for survival. Blocking the NF-kB activity leads to decreased
expression of Bcl-X and c-myc, growth arrest, and apoptosis
[77,78,80,88]. Our studies using c-Rel-siRNA further validate the
particularly important role of c-Rel in maintaining the survival of
Wehi-231 cells, functioning presumably by blocking c-Rel-
regulated anti-apoptotic molecules including Bcl-X, Bfl-1, Mcl-1,
and c-myc [29,60,62,64,85,88,89,96–100]. Our future plan is to
test the c-Rel-siRNA on other B cell tumors with constitutive c-Rel
activation, including diffuse large B cell lymphoma, multiple
myeloma, and chronic lymphocytic leukemia, in order to expand
the uses of c-Rel-siRNA as potential therapy for these tumors.
The inhibitory effect of c-Rel-siRNA on B lymphocyte
proliferative responses as well as antigen-mediated immune
responses essentially mimics the phenotype of the c-Rel knockout
mice, thus validating the specific knockdown of c-Rel molecules by
the siRNA. Our studies also suggest a practical application of the
c-Rel-siRNA as a potential treatment for autoimmune diseases
resulting from hyperactive immune responses to auto-antigens.
The experiments presented in this report demonstrate that even
reducing c-Rel expression in a sub-fraction of lymphoid and
myeloid cells is sufficient to dampen T cell proliferative responses
to the specific KLH antigen by 27–40%. These results suggest that
blocking c-Rel even partially may be sufficient to subdue
unwanted hyperactive immune responses, without compromising
the host’s defenses to microbial infection. In fact, the c-RelKO
mouse studies have shown that, while these mice are protected
from developing allergic inflammation, autoimmune diseases
(EAE, Type I diabetes, collagen induced arthritis), their innate
immune responses to pathogens (e.g. influenza virus, Toxoplasma
gondii, Listeria monocytogenes) remains largely intact [17–22,
Figure 5. In vivo silencing c-Rel results in impaired proliferative response to antigenic stimulation. A group of 8–10 mice per
experiment were immunized via hind footpad injection of KLH (100 mg) emulsified with CFA (Calbiochem, La Jolla, CA) at the ratio of 1:1. After 9 days,
total lymphocytes isolated from spleens (a) and draining lymph nodes (b) were cultured for 60 hr with various concentrations of KLH. Proliferation
was measured by monitoring
3H-thymidine incorporation.
doi:10.1371/journal.pone.0005028.g005
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ically would not cause global immunosuppression, since innate
immunity against pathogens remains intact in c-RelKO mice.
The involvement of IKK/NF-kBi nav a r i e t yo fh u m a nd i s e a s e s
has suggested that IKK/NF-kB is a potential therapeutic target.
While IKKb inhibitors could represent thef i r s tR e l / N F - k B - t a r g e t e d
therapy, systemic toxicity is amajor concernfor this class of inhibitors,
because of the ubiquitous expression of IKK/NF-kB. Actually, early
clinical trial datafromanIKKbinhibitor reported it to be rather toxic
to cancer patients. This is likely attributed to the ubiquitous
expression of p65 in all tissues as well p65’s role in maintaining basal
survival of many cell types in vivo. As suggested from early studies on
the IKKb and p65 knockout mice, both mice die at an early
embryonic stage, due to hepatocyte cytotoxicity [26,27,101]. By
comparison, c-Rel knockout mice are viable. Systemic suppression
of c-Rel activity in mice protects against the development of
autoimmune diseases, and shows no measurable adverse effects on
development, metabolism, reproduction, or life-span. Since drug
safety is an important feature for treating patients with chronic
diseases, we propose an alternative strategy to tackle the Rel/NF-kB
pathway without causing systemic toxicity: by targeting c-Rel.
The c-Rel-siRNA based inhibitors, if successfully developed, will
offer several advantages over IKKb inhibitors. (i) The c-Rel
inhibitor will have significantly reduced toxicity compared to
IKKb inhibitors, as supported by knockout mouse studies. (ii)
Blocking c-Rel suppresses the expression of multiple inflammatory
cytokines and inhibits the growth of B cell tumors. (iii) The IKKb
inhibitor-based therapy will be ineffective toward tumors with
genetic alterations downstream of IKK (e.g. IkB mutation, Rel TF
overexpression). The c-Rel inhibitors, however, will circumvent
such limitations.
Ultimately, our goal is to develop c-Rel-siRNA as a potential
therapy for inflammatory disease, autoimmune disease, and B cell
tumors. Although siRNA delivery remains a challenge, recent
advances in this field have show significant improvement with
regard to oligo stability and delivery systems [1,2,69–72]. For
example, siRNA stability in serum can be improved significantly
by incorporating 29-O-methyl modification and phosphorothioate
linkage into the siRNA backbone [1,2]. Various formulation and
delivery systems could be tested for delivery synthetic Rel-siRNA
into tumors or target tissues by conjugation with cholesterol and
peptides, or formulation with liposomes, lipoplexes, PEG, poly-
ethylenimide (PEI), atelocollagen, or protamine-antibody [1,2,
102–106]. Several clinical trials on small interfering RNA
(siRNA)-based drugs are currently ongoing to target viral disease
and macular degeneration [1,2]. Thus, RNAi-mediated therapies
hold promise for the treatment of diseases resulted from aberrant
activation of a particular gene and its biological pathway.
Materials and Methods
Ethics Statement
The ethical use of animals in this study has been reviewed and
approved by the Institutional Animal Care and Use Committee of
the Weill Medical College of Cornell University (protocol #0304-
112A, 0606-505A).
Construction of siRNA expressing vectors
The method used for the construction of siRNA expression
vector has been described (17). Briefly, Mouse U6 promoter was
amplified by PCR from mouse genomic DNA using the following
oligos: sense: 59 GGAAGATCTATCCGACGCCGCCATCTC-
TA and antisense: 59 GTGGAATTCGTTAAC GAAGACCA-
CAAACAAGGCTTTTCTCCAA. Within the sense oligo
sequence, Bgl II target sequence was underlined. Within the
antisense oligo sequence, the first underlined sequence represents
an EcoR I restriction site and the second is a Bbs I site. The PCR
product was cloned into the Bgl II and EcoR I sites of pEGFP-C3
vector (Clontech) to generate a new vector, pEGFP-mU6-1
[73,74].
The siRNA oilgos for c-Rel were designed as follows: upper
strand: 59 TTTGGTGTGAAGGGCGATCAGCAGGTTCAA-
GAGACCTGCTGATCGCCCTTCACACTTTTTC; lower
strand: 59AATTGAAAAAGTGTGAAGGGCGATCAGCAGG-
TCTCTTGAACCTGCTGATCGCCCTTCACAC. Oligos were
heated at 95uC for 5 minutes and then annealed at 37uC for one
hour. Annealed sequence was ligated into the Bbs I and EcoR I sites
of pEGFP-mU6-1 vector. Then, the siRNA expressing cassette
was cut with Bgl II and Hpa I and subcloned into the MIGR1
vector to generate the MIGR1mU6-siRel vector [73,74]. This
vector will co-express siRNA transcript and green fluorescent
protein (GFP).
Preparation of retrovirus and determination of virus titer
Packaging of retrovirus was performed as described [75,107].
Briefly, the MIGR1mU6-siRel plasmid or the MIGR1mU6
control plasmid was cotransfected with pHIT123 and P
CGP into
293T cell using calcium phosphate method. At 48 hours post
transfection, the supernatant was harvested and assayed for viral
titer by infection on NIH3T3 cells. The retrovirus supernatant was
stored at 280uC for future use.
In vitro silencing of c-Rel
To test the silencing effect of c-Rel siRNA expressing retrovirus,
2610
5 of NIH3T3 cells were seeded in 6-cm dishes. After culture
for 24 hours, 100 ml of retrovirus (5610
6/ml) was added into 3T3
cells in the presence of polybrene (4 mg/ml). At 48 hours post-
infection, cells were harvested and monitored by flow cytometry
for the infection efficiency. The expression of c-Rel at protein level
was tested by Western blot using c-Rel specific polyclonal
antibody.
In vitro infection of Wehi-231 cells
To test the effects of c-Rel silencing on Wehi-231 cell survival
and cell cycle progression, 2 ml of the cells (2610
6/ml) were
seeded in a 6-well plate and cultured with anti-CD40 (10 mg/ml)
for 48 hours in the presence of polybrene (4 mg/ml) and different
dosages of the c-Rel siRNA expressing retrovirus and the control
virus (0.3125, 0.625, 1.25, and 2.5610
6). Cells were harvested and
analyzed by PI staining [73,74] for cell survival and cell cycle
progression.
In vitro infection of primary B cells
To test the effects of c-Rel silencing on B cell response, primary
B cells were isolated from mouse spleen and were stimulated for
24 hr with anti-CD40 (10 mg/ml) before addition of the
retroviruses. Cells were harvested at 48 hr post-infection and
were monitored by propidium iodide (PI) staining analysis for cell
survival and cell cycle progression, or by Ki-67 staining for cell
proliferation.
Generation of siRNA-expressing bone marrow chimeric
mice
Generation of the chimeric mice was performed as described
(17). Briefly, Donor mice (57BL/6, female, 8–10 weeks old) (The
Jackson Labs, USA) were injected with 5-fluorouracil (5-FU,
250 mg/kg weight) per animal. Four days later, bone marrow cells
Rel in Tumor and Immunity
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cultured at a concentration of 2610
6/ml in 2 ml in 6-well plate
with cytokine cocktail containing IL3 (6 ng/ml), IL6 (10 ng/ml)
and SCF (100 ng/ml). After 24 hours, retrovirus supernatant was
added into the BMCs and cultured for an additional 4–6 days.
Cells were then collected and injected into lethally irradiated mice
(850 Rad) through tail vein. Bone marrow chimeras were analyzed
at 4–8 weeks post-bone marrow transfer (BMT). Cell reconstitu-
tion in each immune organ was monitored by flow cytometry for
the percentage of GFP positive cells.
Analysis of KLH-specific responses
For anti-KLH T cell responses, mice were immunized via hind
footpad injection of KLH (100 mg) emulsified with CFA
(Calbiochem, La Jolla, CA) at the ratio of 1:1. After 9 days, the
splenocytes and cells from draining lymph node were separately
isolated and were cultured for 60 hr in various concentrations of
KLH in RPMI 1640 medium supplemented with 10% FCS.
Proliferation was measured by the addition of
3H-thymidine for
the last 12 hours.
Ki-67 staining
Ki-67 staining was performed as described [73,74]. Briefly,
1610
6 cells harvested from the cell culture were washed twice with
PBS and then fixed for 20 min in 0.5 ml of fixation buffer
(eBioscience, San Diego, CA). After washing with PBS, cells were
permeabilized at 4uC for 10 min in permeabilization buffer and
then stained with PE-conjugated anti-Ki-67 antibody (PharMin-
gen) for 30 min. Ki-67 expression cells were quantified by flow
cytometry.
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